Abstract
BackgroundQuality and duration of response to rituximab in seropositive RA is variable. Higher pre-and post-treatment plasmablasts are associated with non-response and early relapse, but have not previously been linked to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have